Price
No data yet.
Social Signal Score
Analyst Ratings
21 analystsRevenue
$121.47MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Frederick G. Vogt
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 975
- Beta
- 0.76
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 6.76
Financials
Revenue
$121.47M+50937.4%Net Income
$-22.27MEBITDA
$-12.16MFree Cash Flow
$-9.21MEPS (diluted)
$-0.05Shares Outstanding (diluted)
455.92M+633.8%Operating Expenses
$87.91MCash & Debt
$376.32MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $263.50M | $-390.98M | $-1.09 |
| 2024 | $164.07M | $-372.18M | $-1.28 |
| 2023 | $1.19M | $-444.04M | $-1.89 |
| 2022 | $0.00 | $-395.89M | $-2.49 |
| 2021 | $0.00 | $-342.25M | $-2.23 |
| 2020 | $0.00 | $-259.58M | $-1.88 |
| 2019 | $0.00 | $-197.56M | $-1.50 |
| 2018 | $0.00 | $-123.58M | $-1.27 |
| 2017 | $0.00 | $-92.06M | $-1.41 |
| 2016 | $0.00 | $-52.89M | $-0.96 |
| 2015 | $0.00 | $-27.66M | $-0.62 |
| 2014 | $0.00 | $-12.04M | $-0.48 |
| 2013 | $0.00 | $-25.38M | $-2.60 |
| 2012 | $0.00 | $-3.31M | $-4.14 |
Valuation
IOVAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (34)
- Newsmarketbeat.com·6d ago·Neutral
Iovance Biotherapeutics Targets 2027 Lung Cancer Filing as AMTAGVI Sales Climb Iovance Biotherapeutics NASDAQ: IOVA is preparing to seek a lung cancer indication for its cell therapy AMTAGVI in 2027 while expanding its melanoma treatment network and advancing studies in earlier-stage melanoma and rare sarcomas, executives said at a Jefferies event.
View source ↗ - Newszacks.com·16d ago·Positive
IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs Iovance beat Q3 2026 earnings and revenue estimates as Amtagvi sales top $100 million, margins improve and R&D costs decline.
View source ↗ - Newsseekingalpha.com·16d ago·Neutral
Iovance Q3 Earnings: Why I'm Reiterating My Buy Call Despite Market Reaction Iovance Biotherapeutics, Inc., delivered strong Q3 results, with revenues up ~80% YoY and gross margin rising to 60%. IOVA reaffirmed 2026 guidance of $410–$420M revenue, and maintains a robust cash position ($376M) expected to last into 2029. Amtagvi's market-leading durability and expanding treatment center network support its competitive positioning despite intense oncology competition.
View source ↗ - Newsseekingalpha.com·16d ago·Neutral
Iovance: Reset Expectations Make The Stock A Buy Again (Rating Upgrade) Iovance Biotherapeutics, Inc. fell 46% after my downgrade to Hold in September, reflecting over-optimism in valuation. AMTAGVI's (lifileucel) melanoma launch gained momentum, but the NSCLC opportunity appeared overestimated based on Q2 call signals. Recent NSCLC data showed a 24.6% ORR across 69 evaluable patients, slightly below the prior interim readout.
View source ↗ - Newszacks.com·16d ago·Neutral
IOVA Q3 Earnings Call Highlights Amtagvi Growth and Pipeline Progress Iovance reaffirms its 2026 revenue outlook as Q3 sales jump 80%, fueled by Amtagvi adoption, improving margins and progress in its cancer pipeline.
View source ↗ - Newsseekingalpha.com·17d ago·Neutral
Iovance Biotherapeutics, Inc. (IOVA) Q3 2026 Earnings Call Transcript Iovance Biotherapeutics, Inc. ( IOVA ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Jen Saunders Frederick Vogt - Interim CEO, President, General Counsel, Corporate Secretary & Director Corleen Roche - Chief Financial Officer Daniel Kirby - Chief Commercial Officer Noah Berkowitz - Chief Medical Officer Raj Puri - Chief Regulatory Officer Conference Call Participants Lin Tsai - Jefferies LLC, Researc…
View source ↗ - Newsmarketbeat.com·17d ago·Neutral
Iovance Biotherapeutics Q3 Earnings Call Highlights Iovance Biotherapeutics NASDAQ: IOVA reported record third-quarter revenue of approximately $122 million, up 80% from a year earlier, as sales of its melanoma treatment AMTAGVI surpassed $100 million in a quarter for the first time.
View source ↗ - Newszacks.com·17d ago·Neutral
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Beats Revenue Estimates Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.25 per share a year ago.
View source ↗ - Newszacks.com·20d ago·Positive
Iovance Gears Up to Report Q3 Earnings: Here's What to Expect IOVA is poised for a Q3 earnings beat as Amtagvi sales drive revenue, Proleukin adds growth and pipeline progress draws investor attention.
View source ↗ - Newsseekingalpha.com·24d ago·Positive
Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer Transcript Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer Transcript
View source ↗ - Newsmarketbeat.com·24d ago·Negative
Iovance's Lifileucel Shows 25% Lung Cancer Response Rate, Targets 2027 FDA Filing Iovance Biotherapeutics NASDAQ: IOVA reported updated data from its registrational IOV-LUN-202 trial of lifileucel in previously treated, non-squamous metastatic non-small cell lung cancer, outlining plans for a supplemental Biologics License Application submission in 2027 and a new biomarker-enriched study.
View source ↗ - News (RSS)investing·24d ago·Neutral
Iovance reports 24.6% response rate in lung cancer trial
View source ↗ - News (RSS)investing·24d ago·Neutral
Iovance stock falls after lung cancer trial data disappoints
View source ↗ - News (Marketaux)manilatimes.net·24d ago·Neutral
Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy ET on Thursday, October 29, 2026 PHILAD[+98 characters]
View source ↗ - Newszacks.com·26d ago·Positive
Best Momentum Stocks to Buy for October 27th IOVA, MEI and PRMRF made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 27th, 2026.
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
…ter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026 PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, November 5, 2026 at 8:30 a.m. ET to report its third quarter 2026 financial results and c…
View source ↗ - News (RSS)seekingalpha·34d ago·Negative
Undercovered Dozen: Hess Midstream, Iovance Biotherapeutics, Netlist, And More
View source ↗ - Newsglobenewswire.com·37d ago·Neutral
…Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PHILADELPHIA, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on October 15, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering a…
View source ↗ - Newsseekingalpha.com·48d ago·Negative
Iovance: Buy Now Before Many Growth Catalysts Kick In Iovance raised 2026 revenue guidance to $410–$420 million as Amtagvi adoption accelerates, supported by expanding treatment access, greater physician awareness, and faster manufacturing. Frontline melanoma trials, lung cancer development, and international expansion could broaden Amtagvi's market by at least an order of magnitude from the current peak sales expectation of $1B. Internal manufacturing supports improving margins and narrowing lo
View source ↗ - News (Marketaux)insidermonkey.com·49d ago·Positive
Why Iovance Biotherapeutics (IOVA) Effortlessly Soared 256% in Q3 Iovance Biotherapeutics</em[+228 characters]
View source ↗ - Newszacks.com·53d ago·Positive
IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026 Iovance hits a 52-week high after raising its 2026 revenue outlook to $410-$420 million on strong demand for its marketed therapies.
View source ↗ - Newszacks.com·53d ago·Positive
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains? Iovance Biotherapeutics (IOVA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
View source ↗ - News (RSS)seekingalpha·54d ago·Neutral
Iovance: The Turnaround Is Priced In, Downgrading To Hold
View source ↗ - Newsbenzinga.com·54d ago·Neutral
Iovance Biotherapeutics' Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shares are trading higher on Tuesday as the company raises full-year 2026 revenue guidance, bucking a -0.8% slide in the Healthcare sector even as the S&P 500 is down 0.10%.
View source ↗ - News (RSS)zerohedge·54d ago·Neutral
…fuel cell maker with a recommendation of outperform, expecting demand to stay “well ahead” of supply as it ramps up its production capacity. Iovance Biotherapeutics (IOVA) climbs 5% after boosting its revenue guidance for the full year. Monday.com Ltd. (MNDY) slips 1.8% after JPMorgan downgraded the software company to neutral from overweight, citing growth challenges for annual recurring revenue. Netflix (NFLX) inches 1% higher after Deutsche Bank upgraded the streaming-video company to buy, sa…
View source ↗ - News (RSS)investing·54d ago·Neutral
Why is Iovance Biotherapeutics stock surging today?
View source ↗ - Newsglobenewswire.com·54d ago·Positive
…Million Strong U.S. Demand for Amtagvi and Proleukin Drives Increased Outlook PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today raised its full year 2026 total revenue guidance range to $410 to $420 million, driven by strong U.S. demand for Amtagvi® (lifileucel) and Proleuki…
View source ↗ - Newsfool.com·59d ago·Positive
Why Iovance Biotherapeutics Stock Was on Fire Today Happily for investors, it flagged the biotech's shares as a buy. Goldman believes they have nearly 40% upside.
View source ↗ - Newsglobenewswire.com·65d ago·Neutral
…apeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on September 17, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering…
View source ↗ - Newsglobenewswire.com·79d ago·Neutral
Iovance Biotherapeutics to Present at Upcoming Conferences SAN CARLOS, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences:
View source ↗ - Newsglobenewswire.com·93d ago·Neutral
…rapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on August 20, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an…
View source ↗ - Newsbenzinga.com·93d ago·Neutral
Iovance Biotherapeutics Stock Is Trending Friday: What's Going On? Shares of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) are trending Friday morning, continuing a momentum surge that recently pushed the biotech stock to a new 52-week high after gaining over 250% year-to-date.
View source ↗ - Newsbenzinga.com·94d ago·Neutral
Why Iovance Biotherapeutics Stock Hit 52-Week High Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is trading at a 52-week high on Thursday, despite having no news to justify the move. Year to date, the stock has surged over 200%.
View source ↗ - Newsseekingalpha.com·94d ago·Neutral
…atalysts Ahead, And Competitor Updates Iovance Biotherapeutics, Inc. delivered a breakout Q2 '26 for Amtagvi sales, with management guiding for further growth ahead. IOVA's maturing clinical pipeline and imminent NSCLC readout position the company for further upside, given the market potential in NSCLC is several times larger than in melanoma. Potential competitor, IMTX, is expecting to produce results from a trial of its cell therapy, Anzu-cel, in melanoma in H1 '27.
View source ↗
Earnings
Tue, Feb 23(in 3 months)
Consensus estimate $-0.07 per share
Typical surprise +13.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.05 vs $-0.08beat
- Thu, Aug 6$-0.11 vs $-0.13beat
- Thu, May 7$-0.19 vs $-0.19beat
- Tue, Feb 24$-0.18 vs $-0.22beat
- Thu, Nov 6$-0.25 vs $-0.29beat
- Thu, Aug 7$-0.33 vs $-0.29miss
Estimates and results for IOVA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IOVA officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IOVA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
